| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Guidelines for the use and interpretation of assays for monitoring autophagy.
|
Autophagy
|
2012
|
20.08
|
|
2
|
Initial genome sequencing and analysis of multiple myeloma.
|
Nature
|
2011
|
17.28
|
|
3
|
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
|
N Engl J Med
|
2005
|
15.30
|
|
4
|
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
|
N Engl J Med
|
2007
|
8.41
|
|
5
|
Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth.
|
Sci Signal
|
2009
|
5.57
|
|
6
|
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.
|
Blood
|
2012
|
5.11
|
|
7
|
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
|
J Clin Oncol
|
2006
|
4.87
|
|
8
|
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.
|
Mayo Clin Proc
|
2015
|
4.70
|
|
9
|
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
|
Blood
|
2010
|
4.52
|
|
10
|
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.
|
Blood
|
2011
|
4.00
|
|
11
|
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.
|
Blood
|
2007
|
3.66
|
|
12
|
Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism.
|
Mol Cell
|
2011
|
2.61
|
|
13
|
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.
|
Blood
|
2013
|
2.59
|
|
14
|
FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway.
|
Cancer Cell
|
2007
|
2.56
|
|
15
|
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.
|
J Clin Oncol
|
2008
|
2.45
|
|
16
|
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.
|
Blood
|
2012
|
2.41
|
|
17
|
Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth.
|
Cancer Cell
|
2012
|
2.39
|
|
18
|
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
|
Br J Haematol
|
2009
|
2.32
|
|
19
|
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
|
Leuk Lymphoma
|
2012
|
2.14
|
|
20
|
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.
|
Blood
|
2011
|
2.13
|
|
21
|
Eliminating the complete response penalty from myeloma response assessment.
|
Blood
|
2008
|
2.11
|
|
22
|
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
|
Clin Cancer Res
|
2013
|
2.02
|
|
23
|
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
|
Blood
|
2014
|
2.01
|
|
24
|
Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors.
|
Blood
|
2011
|
2.01
|
|
25
|
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.
|
Lancet Oncol
|
2013
|
1.99
|
|
26
|
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.
|
J Clin Oncol
|
2009
|
1.92
|
|
27
|
Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma.
|
Biol Blood Marrow Transplant
|
2013
|
1.88
|
|
28
|
Salvage second hematopoietic cell transplantation in myeloma.
|
Biol Blood Marrow Transplant
|
2013
|
1.80
|
|
29
|
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.
|
Haematologica
|
2013
|
1.76
|
|
30
|
Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy.
|
Cancer Res
|
2009
|
1.70
|
|
31
|
The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
|
Cancer Res
|
2007
|
1.66
|
|
32
|
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.
|
Blood
|
2006
|
1.63
|
|
33
|
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
|
Blood
|
2009
|
1.59
|
|
34
|
Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.
|
J Clin Oncol
|
2010
|
1.53
|
|
35
|
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.
|
J Clin Oncol
|
2014
|
1.52
|
|
36
|
An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.
|
Clin Lymphoma Myeloma Leuk
|
2012
|
1.48
|
|
37
|
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.
|
Blood
|
2014
|
1.47
|
|
38
|
Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells.
|
Blood
|
2011
|
1.47
|
|
39
|
Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH/NAD(+) redox homeostasis in cancer cells.
|
Mol Cell Biol
|
2011
|
1.42
|
|
40
|
Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation.
|
J Biol Chem
|
2010
|
1.40
|
|
41
|
Novel Combination Treatments in Multiple Myeloma.
|
Oncology (Williston Park)
|
2016
|
1.38
|
|
42
|
The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway.
|
Mol Cancer Ther
|
2007
|
1.33
|
|
43
|
Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.
|
Br J Haematol
|
2011
|
1.26
|
|
44
|
Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma.
|
Cancer Chemother Pharmacol
|
2010
|
1.22
|
|
45
|
Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation.
|
Biol Blood Marrow Transplant
|
2003
|
1.21
|
|
46
|
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
|
Br J Haematol
|
2007
|
1.21
|
|
47
|
Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.
|
Blood
|
2013
|
1.21
|
|
48
|
Review of peripheral neuropathy in plasma cell disorders.
|
Hematol Oncol
|
2008
|
1.19
|
|
49
|
PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma.
|
Future Oncol
|
2007
|
1.16
|
|
50
|
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.
|
J Clin Oncol
|
2011
|
1.14
|
|
51
|
Monoclonal antibodies in the treatment of multiple myeloma.
|
Br J Haematol
|
2011
|
1.14
|
|
52
|
Monoclonal gammopathy of undetermined significance: a consensus statement.
|
Br J Haematol
|
2010
|
1.14
|
|
53
|
Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia.
|
Cancer
|
2012
|
1.13
|
|
54
|
Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis.
|
Blood
|
2011
|
1.13
|
|
55
|
Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study.
|
Br J Haematol
|
2011
|
1.12
|
|
56
|
Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.
|
Blood
|
2011
|
1.11
|
|
57
|
14-3-3 Integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1-transformed hematopoietic cells.
|
Blood
|
2007
|
1.11
|
|
58
|
A practical update on the use of bortezomib in the management of multiple myeloma.
|
Oncologist
|
2006
|
1.09
|
|
59
|
Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation.
|
Nat Commun
|
2013
|
1.08
|
|
60
|
Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.
|
Blood
|
2012
|
1.07
|
|
61
|
Fibroblast growth factor receptor 3 associates with and tyrosine phosphorylates p90 RSK2, leading to RSK2 activation that mediates hematopoietic transformation.
|
Mol Cell Biol
|
2009
|
1.05
|
|
62
|
Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation.
|
Blood
|
2002
|
1.02
|
|
63
|
Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
|
Transfusion
|
2011
|
1.01
|
|
64
|
Bone marrow mobilization with granulocyte macrophage colony-stimulating factor improves endothelial dysfunction and exercise capacity in patients with peripheral arterial disease.
|
Am Heart J
|
2009
|
1.01
|
|
65
|
The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT.
|
Blood
|
2005
|
1.00
|
|
66
|
Current strategies for treatment of relapsed/refractory multiple myeloma.
|
Expert Rev Hematol
|
2014
|
0.99
|
|
67
|
Facilitating T-cell immune reconstitution after haploidentical transplantation in adults.
|
Blood Cells Mol Dis
|
2004
|
0.98
|
|
68
|
Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.
|
Leuk Res
|
2010
|
0.97
|
|
69
|
Clinical uses of GM-CSF, a critical appraisal and update.
|
Biologics
|
2008
|
0.97
|
|
70
|
Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase.
|
Br J Haematol
|
2012
|
0.96
|
|
71
|
Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors.
|
Clin Cancer Res
|
2008
|
0.96
|
|
72
|
Epidermal growth factor stimulates RSK2 activation through activation of the MEK/ERK pathway and src-dependent tyrosine phosphorylation of RSK2 at Tyr-529.
|
J Biol Chem
|
2007
|
0.94
|
|
73
|
Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes.
|
Blood
|
2010
|
0.93
|
|
74
|
Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
|
Cancer
|
2010
|
0.92
|
|
75
|
Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials.
|
Cancer
|
2013
|
0.92
|
|
76
|
Immunomodulatory effects of human recombinant granulocyte-macrophage colony-stimulating factor (rhuGM-CSF): evidence of antitumour activity.
|
Expert Opin Biol Ther
|
2005
|
0.92
|
|
77
|
A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.
|
Cancer
|
2012
|
0.90
|
|
78
|
Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
|
Biol Blood Marrow Transplant
|
2003
|
0.89
|
|
79
|
Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
|
Cancer
|
2006
|
0.89
|
|
80
|
Racial differences in the incidence and outcomes for patients with hematological malignancies.
|
Curr Probl Cancer
|
2007
|
0.88
|
|
81
|
Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.88
|
|
82
|
Reconstructing immunity after allogeneic transplantation.
|
Immunol Res
|
2004
|
0.88
|
|
83
|
The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cells.
|
Mol Cancer Ther
|
2011
|
0.87
|
|
84
|
The era of combination therapy in myeloma.
|
J Clin Oncol
|
2012
|
0.86
|
|
85
|
Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences.
|
Ann Pharmacother
|
2013
|
0.86
|
|
86
|
Hepatitis C reactivation in patients who have diffuse large B-cell lymphoma treated with rituximab: a case report and review of literature.
|
Clin Lymphoma Myeloma Leuk
|
2011
|
0.86
|
|
87
|
Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.85
|
|
88
|
The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cells.
|
Cancer Res
|
2007
|
0.85
|
|
89
|
Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients.
|
Eur J Haematol
|
2011
|
0.83
|
|
90
|
Panobinostat for the treatment of multiple myeloma.
|
Expert Opin Investig Drugs
|
2012
|
0.83
|
|
91
|
Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma.
|
Expert Rev Anticancer Ther
|
2015
|
0.82
|
|
92
|
Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib.
|
Biologics
|
2013
|
0.81
|
|
93
|
Multiple myeloma: the role of transplant and novel treatment strategies.
|
Semin Oncol
|
2004
|
0.81
|
|
94
|
The Tao of myeloma.
|
Blood
|
2014
|
0.80
|
|
95
|
Proteasome inhibition: novel therapy for multiple myeloma.
|
Onkologie
|
2006
|
0.80
|
|
96
|
A randomized, placebo-controlled trial of subcutaneous administration of GM-CSF as a vaccine adjuvant: effect on cellular and humoral immune responses.
|
Vaccine
|
2002
|
0.80
|
|
97
|
Maintenance therapy in lymphoma.
|
Clin Lymphoma Myeloma
|
2007
|
0.80
|
|
98
|
Receiver operating characteristic curve analysis of circulating blood dendritic cell precursors and T cells predicts response to extracorporeal photopheresis in patients with chronic graft-versus-host disease.
|
Transfusion
|
2010
|
0.80
|
|
99
|
Designing risk-adapted therapy for multiple myeloma: the Mayo perspective.
|
Mayo Clin Proc
|
2007
|
0.80
|
|
100
|
The importance of complete response in outcomes in myeloma.
|
Cancer J
|
2009
|
0.80
|
|
101
|
Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma.
|
Biol Blood Marrow Transplant
|
2013
|
0.78
|
|
102
|
Evidence-based mini-review: treatment options for patients with relapsed/refractory myeloma previously treated with novel agents and high-dose chemotherapy and autologous stem-cell transplantation.
|
Hematology Am Soc Hematol Educ Program
|
2010
|
0.78
|
|
103
|
Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma.
|
Int J Hematol
|
2012
|
0.78
|
|
104
|
Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma.
|
Leuk Lymphoma
|
2014
|
0.77
|
|
105
|
A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma.
|
Transfusion
|
2012
|
0.77
|
|
106
|
Current advances in novel proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma.
|
Oncology (Williston Park)
|
2011
|
0.77
|
|
107
|
Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma.
|
Leuk Lymphoma
|
2011
|
0.76
|
|
108
|
Treatment of relapsed and refractory myeloma.
|
Curr Hematol Malig Rep
|
2009
|
0.76
|
|
109
|
High-risk multiple myeloma: does it still exist?
|
Clin Lymphoma Myeloma Leuk
|
2011
|
0.76
|
|
110
|
Novel treatment approaches for patients with multiple myeloma.
|
Clin Lymphoma Myeloma
|
2006
|
0.76
|
|
111
|
Improving induction therapy in multiple myeloma.
|
Curr Hematol Malig Rep
|
2010
|
0.76
|
|
112
|
A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.
|
Clin Adv Hematol Oncol
|
2007
|
0.76
|
|
113
|
Rare myelomas: sometimes when you hear hooves, it's a zebra...
|
Oncology (Williston Park)
|
2013
|
0.75
|
|
114
|
Putting the E (evidence) in a new Era for myeloma.
|
Leuk Lymphoma
|
2011
|
0.75
|
|
115
|
Recovery and rebound of platelet counts in mice after thrombocytopenia induced by combination bortezomib + romidepsin.
|
Exp Hematol
|
2011
|
0.75
|
|
116
|
Treatment of multiple myeloma: whence truth over belief?
|
Oncology (Williston Park)
|
2009
|
0.75
|
|
117
|
Melphalan or no melphalan: that is the question.
|
Oncology (Williston Park)
|
2010
|
0.75
|
|
118
|
Conflicts of interest, authorship, and disclosures in industry-related scientific publications.
|
Mayo Clin Proc
|
2010
|
0.75
|
|
119
|
Sequential or combination therapy for multiple myeloma.
|
Expert Rev Hematol
|
2012
|
0.75
|
|
120
|
Novel treatment approaches for patients with relapsed and refractory multiple myeloma.
|
Curr Treat Options Oncol
|
2006
|
0.75
|
|
121
|
Breakthroughs in the management of multiple myeloma.
|
Drugs
|
2003
|
0.75
|
|
122
|
Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients.
|
Cancer
|
2014
|
0.75
|
|
123
|
Optimizing the management of treatment-related peripheral neuropathy in patients with multiple myeloma.
|
Support Cancer Ther
|
2006
|
0.75
|
|
124
|
High-risk myeloma: when to transplant-or not.
|
Semin Oncol
|
2013
|
0.75
|
|
125
|
A randomized clinical trial comparing granulocyte-colony-stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantation.
|
Transfusion
|
2011
|
0.75
|
|
126
|
Multiple myeloma presenting with advanced renal failure: a case report and new treatment options.
|
Clin Lymphoma Myeloma
|
2008
|
0.75
|
|
127
|
Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells.
|
Transfusion
|
2007
|
0.75
|
|
128
|
Targeted therapy for haematological malignancies: clinical update from the American Society of Hematology, 2004.
|
Expert Opin Investig Drugs
|
2005
|
0.75
|
|
129
|
Insights Into the Appropriate Use of New Antimyeloma Therapies.
|
Oncology (Williston Park)
|
2017
|
0.75
|
|
130
|
Supportive therapies in multiple myeloma.
|
J Natl Compr Canc Netw
|
2009
|
0.75
|